Evidence map›Paper›PMID 35413095›Full record

ArticleBlood advances2022

Cell origin-dependent cooperativity of mutant Dnmt3a and Npm1 in clonal hematopoiesis and myeloid malignancy.

Jennifer M SanMiguel, Elizabeth Eudy, Matthew A Loberg, Linde A Miles, Tim Stearns, Jayna J Mistry, Michael J Rauh, Ross L Levine, Jennifer J Trowbridge

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2025
    Article
  3. Review
  4. Review
  5. Late-onsetHaematologica · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (International journal of molecular sciences · 2023
    Review
  10. Review
  11. Clonal Hematopoiesis: Role in Hematologic and Non-Hematologic Malignancies.Mediterranean journal of hematology and infectious diseases · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jennifer M SanMiguelThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME.ORCID 0000-0002-5882-0752
Elizabeth EudyThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME.
Matthew A LobergThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME.ORCID 0000-0001-5840-4591
Linde A MilesHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY.ORCID 0000-0003-3578-2842
Tim StearnsThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME.
Jayna J MistryThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME.
Michael J RauhDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada; and.ORCID 0000-0002-8346-5537
Ross L LevineHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY.
Jennifer J TrowbridgeThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME.
Jackson Laboratory · USMemorial Sloan Kettering Cancer Center · USQueen's University · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9M
Translational CoreP30AG038070 · NIA · JACKSON LABORATORY · PI Gary A Churchill · 2010 to 2026
$19.3M
Developing Effective Approaches to Extend Hematopoietic Healthspan by Targeting Cell-Extrinsic and Cell-Intrinsic Alterations at Middle AgeR01DK118072 · NIDDK · JACKSON LABORATORY · PI Jennifer Jean Trowbridge · 2018 to 2026
$4.2M
Inflammatory Signaling in DNMT3A-Mutated Human Hematopoietic Stem CellsU01AG077925 · NIA · JACKSON LABORATORY · PI LEVINE, ROSS L, TROWBRIDGE, JENNIFER JEAN · 2021 to 2025
$2.9M
REPRODUCTIVE BIOLOGYT32HD007065 · NICHD · JACKSON LABORATORY · PI BRAUN, ROBERT E · 1985 to 2020
$2.6M
Discovery of Aging-Associated Mechanisms Causing Expansion and Progression of Clonal Hematopoiesis of Indeterminant Potential (CHIP)R01AG069010 · NIA · JACKSON LABORATORY · PI TROWBRIDGE, JENNIFER JEAN · 2020 to 2024
$2.4M
Training Program in Precision Genetics of Aging, Alzheimer's Disease and Related DementiasT32AG062409 · NIA · JACKSON LABORATORY · PI Gareth R Howell, KRISTEN M O'CONNELL · 2020 to 2026
$1.5M
Dissecting the role of clonal evolution in NPM1-mutant AMLK99CA252005 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI MILES, LINDE A · 2021 to 2022
$337k
NCI NIH HHS K99 CA252005NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA034196NIA NIH HHS P30 AG038070NIA NIH HHS R01 AG069010NIA NIH HHS T32 AG062409NIA NIH HHS U01 AG077925NICHD NIH HHS T32 HD007065NIDDK NIH HHS R01 DK118072
6 · The paper itself

Abstract

In adult acute myeloid leukemia (AML), the acquisition of driver somatic mutations may be preceded by a benign state termed clonal hematopoiesis (CH). To develop therapeutic strategies to prevent leukemia development from CH, it is important to understand the mechanisms by which CH-driving and AML-driving mutations cooperate. Here, we use mice with inducible mutant alleles common in human CH (DNMT3AR882; mouse Dnmt3aR878H) and AML (NPM1c; mouse Npm1cA). We find that Dnmt3aR878H/+ hematopoietic stem cells (HSCs), but not multipotent progenitor cell (MPP) subsets, have reduced cytokine expression and proinflammatory transcriptional signatures and a functional competitive advantage over their wild-type counterparts. Dnmt3aR878H/+ HSCs are the most potent cell type transformed by Npm1cA, generating myeloid malignancies in which few additional cooperating somatic mutation events were detected. At a molecular level, Npm1cA, in cooperation with Dnmt3aR878H, acutely increased the accessibility of a distinct set of promoters in HSCs compared with MPP cells. These promoters were enriched for cell cycling, PI3K/AKT/mTOR signaling, stem cell signatures, and targets of transcription factors, including NFAT and the chromatin binding factor HMGB1, which have been implicated in human AML. These results demonstrate cooperativity between preexisting Dnmt3aR878H and Npm1cA at the chromatin level, where specific loci altered in accessibility by Npm1cA are dependent on cell context as well as Dnmt3a mutation status. These findings have implications for biological understanding and therapeutic intervention in the transformation from CH to AML.

Indexed as

Leukemia, Myeloid, AcuteMyeloproliferative DisordersAnimalsChromatinClonal HematopoiesisDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AMiceNucleophosminPhosphatidylinositol 3-KinasesChromatinDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADnmt3a protein, mouseNpm1 protein, mouseNucleophosminPhosphatidylinositol 3-Kinases

Identifiers

PMID35413095
PMCPMC9631557
OpenAlexW4223619433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.